|
|
Article: Drug-eluting stents better than bare-metal stents for heart attack patients.
- Article from:
- NewsRx Health
- Article date:
- October 18, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Late-breaking data from the landmark HORIZONS-AMI clinical trial, presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrated that after two years, in heart attack patients, the use of a drug-eluting stent (paclitaxel) was safer and more effective than a bare-metal stent; and that the administration of the anticoagulant medication bivalirudin enhanced safety and efficacy compared to the use of heparin + GPIIb/IIIa inhibitors.
Results from "Two-Year Follow-up from a Prospective, Randomized Trial of Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs. Bivalirudin and Paclitaxel-Eluting vs. Bare Stents in STEMI" will ...
Related newspaper, magazine, and journal articles:
|
|
Article: Diabetics' heart attack risk can be reduced, ...
NewsRx Health;
June 14, 2009 ;
700+ words
... ... including 1497 heart attack cases, 2,318 cases ... Endocrinology, Heart Attack, Heart Disease ... article was prepared by NewsRx Health editors from staff ... Copyright 2009, NewsRx Health via NewsRx.com ...
|
|